Characterisation of the single copy trefoil peptides intestinal trefoil factor and pS2 and their ability to form covalent dimers  by Chinery, Rebecca et al.
FEBS Letters 357 (1995) 50 54 FEBS 14910 
Characterisation of the single copy trefoil peptides intestinal trefoil factor 
and pS2 and their ability to form covalent dimers 
Rebecca Chinery a'**, Paul A. Bates b'**, Amitabha De c'***, Paul S. Freemont c'* 
~Department of Pharmacology, The Royal College of Surgeons of England, 35-43 Lincoln's Inn Fields, London WC2A 3PN, UK 
bBiomolecular Modelling Laboratory, Imperial Cancer Research Fund, PO. Box 123, Lincoln's Inn Fields', London WC2A 3PX, UK 
~Protein Structure Laboratory, Imperial Cancer Research Fund, P O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK 
Received 18 October 1994; revised version received 11 November 1994 
Abstract A bacterial recombinant expression system was estab- 
lished to produce biologically active rat Intestinal Trefoil Factor 
(rITF). Characterisation of purified rITF shows that both mono- 
mers and dimers can be observed under reducing and non-reduc- 
ing conditions, respectively. Site-directed mutagenesis tudies 
show that Cys57 is necessary for rITF dimer formation. Samples 
of human gastrointestinal tissue following biopsy also demon- 
strated the presence of reducible human pS2 and ITF covalent 
dimers. Three-dimensional models for pS2 and ITF support the 
hypothesis that both pS2 and ITF can exist as disulphide-linked 
dimers in vivo and that any proposed function for these peptides 
must take dimer formation into account. 
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1. Introduction 
The trefoil family is a group of extracellular peptides that are 
highly expressed in the gastrointestinal tract and whose physio- 
logical role is largely unknown [1]. Characteristic for these 
peptides is a conserved pattern of six cysteine residues, which 
form three intramolecular disulphide bridges, as well as a num- 
ber of conserved arginine, glycine and tryptophan residues. The 
spacing between five of the six cysteine residues is invariable, 
with only the spacing between Cys ~ and Cys 2 subject to minor 
variation (see Fig. 3a). The proposed primary structure of the 
motif, with its three disulphide loops, resembles a 'trefoil', 
which is highly resistant to proteolytic and acid degradation [2]. 
In mammals, at least two classes of different refoil proteins 
have been characterised containing either one (human, mouse 
pS2; rat, mouse and human intestinal trefoil factor [ITF]) or 
two (porcine, human, rat and mouse spasmolytic polypeptides 
[SP]) such motifs [1]. As a general principle, expression of each 
peptide is confined to specialised cells which secrete various 
mucin glycoproteins. This has led to the suggestion that trefoil 
peptides are associated with mucin secretion and/or stabiliza- 
tion, thus explaining their over-expression at sites of chronic 
inflammatory and ulcerative conditions, where reformation of 
the mucous gel would be important [3 5]. 
Since the initial identification of single and multiple trefoil- 
containing peptides, little information has been published 
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about their structures and/or functional relationships to each 
other. Recently, however, the NMR and crystal structures for 
the two trefoil-containing protein, porcine pancreatic (P)SR 
have been reported [6 8]. In this peptide, both trefoil-domains 
adopt similar conformations providing a suitable three-dimen- 
sional structural template for a single trefoil motif. As there has 
been some speculation as to the functions of trefoil proteins and 
their possible involvement in either mucous-gel stabilization or 
receptor-mediated responses [1], we have used recombinant rat 
(r)ITF as a single trefoil-containing peptide to study its ability 
to self-associate in the presence or absence of its free cysteine 
residue. In addition, we describe the detection of both mono- 
and dimeric forms of human pS2 and ITF in human tissue 
obtained by biopsy. We also present hree-dimensional models 
for pS2 and ITF homodimers based on the crystal structure of 
the double trefoil-containing protein PSP. 
2. Materials and methods 
2.1. Expression and pur(fication of recombinant rlTF in E. coli 
The predicted mature rat ITF eDNA sequence (bases 64-243) [9,10] 
was cloned in-frame into the bacterial expression vector pGEX-3X. 
Transformants of E. coli were produced and selected by conventional 
procedures [11]. Induction of transformants, lysis of cells, and the 
recovery of rlTF was carried out as described by Gearing et al. [12]. 
Purified samples were dialysed against 0.l M Tris-HC1, pH 7.4, 1 mM 
EDTA, l mM EGTA, and injected onto a Superose 12 gel filtration 
column (Pharmacia) equilibrated with the same buffer, to confirm the 
identity of the peptide. Cytochrome c (12.4 kDa) and blue dextran 
(2 kDa) were used for column calibration. 
2.2. Generation of a mutant Jorm of recombinant rlTF 
A S7Cys(TGT) to 57Lys(AAA) mutation was made in the mature rITF 
eDNA sequence using polymerase chain reaction with a mutagenic 
oligonucleotide 3' primer. The mutant rITF form encoded by the result- 
ing plasmid was produced and purified as described above for wild-type 
recombinant rITF. 
2.3. Production of antisera specific to rlTF 
Purified wild-type rlTF peptide was used to raise a polyclonal anti- 
serum in two rabbits. Rabbits were injected 4 times at bi-weekly inter- 
vals with 50,ug of purified peptide. Serum was obtained 1 month after 
the fourth injection and was used for immunoblotting at a final dilution 
of 1 : 800. The pS2 monoclonal antibody was raised against a synthetic 
peptide corresponding to the terminal 31 amino acids of the predicted 
pS2 protein [13] and used at a final dilution of 1: 300. 
2.4. Homo~Limerisation of tre[bil peptides in vitro and in vivo 
The effect ofpH on dimerisation was examined invitro by incubating 
purified wild-type recombinant rlTF peptide overnight in 300 mM 
potassium phosphate, varying pH values between 4 and 7. To assess 
pre-existing dimerisation i vivo, small samples of human small intesti- 
nal and colonic tissue (1 5 mg) with chronic ulcerative conditions were 
frozen rapidly following biopsy. All peptide and tissue samples were 
resuspended in Laemmli sample buffer, either in the presence or 
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absence of the reducing agent, 2-merceptoethanol. Samples were then 
boiled for 3 min and the supernatant analysed by SDS-PAGE and 
Western blotting. 
2.5. Western blot analysis of lTF and pS2 
1~18% polyacrylamide gels were prepared by the method of 
Laemmli [14] and used under educing conditions. Equal amounts of 
protein (10/tg) were added per lane with molecular mass markers run 
in parallel lanes. After electrophoresis, proteins were transferred elec- 
trophoretically at room temperature for 3 h at 60 V onto nitrocellulose 
membranes (0.1 mm pore size) in a Bio-Rad Trans-Blot cell [15]. After 
transfer, membranes were incubated overnight in 5% fetal calf serum 
in phosphate-buffered saline at 4°C and then incubated successively 
with the appropriate primary antibody followed by a horseradish per- 
oxidase-conjugated anti-immunoglobulin, both for 2 h at 4°C. The 
peroxidase r action was developed using the Amersham's ECL detec- 
tion system. Negative controls were obtained by preadsorbing the anti- 
body with the appropriate immunising peptide. 
2.6. Trefoil structure modelling 
A representative setof mammalian trefoil sequences were aligned 
with the program CLUSTAL V (Fig. 3a) [16]. Small adjustments to the 
alignment were made manually to better eflect the patches of sequence 
similarities. The crystal structure of PSP was used as a template to 
model both ITF and pS2 homodimers. Side chains of PSP domain B 
(PSPB in Fig. 3a), and protein backbone fragments with incompatible 
phi psi angles, were substituted for those of ITF and pS2 using the 
protocol described for the program 3-D JIGSAW [17] and a conformer 
library [18]. The ITF and pS2 domains were energy refined using 50 
steps of steepest decent with the programming package CHARM [19]. 
The final homodimer models were also energy refined with a further 
100 steps of steepest decent and the complete models creened with the 
Protein Health checks option within the programming package 
QUANTA [20]. 
3. Results and discussion 
3.1. Isolation and characterisation of bacterial recombinant rITF 
Recombinant rITF protein was initially purified according 
to the method described by Gearing et al. [12]. SDS-PAGE 
revealed that rITF was synthesised initially as a 33 kDa fusion 
protein (data not shown). Bound fusion protein was cleaved by 
Factor Xa and the released moiety recovered in the column 
supernatant. Eluted material consisted principally of rITF, al- 
though there were contaminating levels, as estimated by 
Coomassie blue staining, of Factor Xa (1%), glutathione-S- 
transferase (10%) and a ~90 kDa host protein (3-5%). The ITF 
sample was further purified by gel filtration under non-denatur- 
ing conditions. The residual contaminants of rITF were found 
to be less than 1% as estimated by Coomassie blue staining. 
3.2. Dimerisation of wild-type rlTF in vitro 
In Fig. l, recombinant rITF is identified by SDS-PAGE 
(lanes 2 3, (~9). Under non-reducing conditions, two entities 
of approximately 7 and 14 kDa can be observed (lane 2). When 
the larger protein was extracted from the gel and reduced, this 
molecule was found to yield a single protein of 7 kDa (lane 3), 
consistent with the shift from dimeric to monomeric rITF. Both 
proteins howed immunological cross-reactivity with the poly- 
clonal antisera (data not shown), demonstrating that recombi- 
nant rITF proteins occur as both monomeric and homodimeric 
forms. Densitometric s anning of Coomassie blue-stained gels 
suggest that recombinant rITF as purified exists predominantly 
in the dimeric form, comprising about 80% of the total peptide 
sample. It is possible that the monomeric recombinant rITF 
observed under non-reducing conditions (Fig. 1, lane 2), has 
lost the ability to dimerise, due to either oxidation of the free 
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Fig. 1. Separation and identification fthe recombinant wild-type and 
mutant rITF by SDS-PAGE. Coomassie blue-stained gel showing elec- 
trophoretic separation of recombinant rITF. Lanes 2 and 3 show the 
presence ofdimeric and monomeric forms of recombinant rITF when 
run under non-reducing conditions (lane 2, N) and reducing conditions 
(lane 3, R). Lanes 4 and 5 shows the presence of C58K mutant rITF 
run under non-reducing (N) and reducing (R) conditions, the position 
of which coincides precisely with that of the monomeric form of rITF. 
Lanes 6-9 show rITF following incubation with potassium phosphate 
at varying pH values (pH 74: lanes 6-9, respectively). Molecular-mass 
markers are shown in lane 1 and include from bottom to top aprotinin 
(6.5 kDa), myoglobin (8.2 kDa), lysozyme (14.3 kDa) and trypsin inhib- 
itor (20.1 kDa). 
sulphydryl or by binding of the free sulphydryl to glutathione 
at the affinity column step during the purification scheme. In- 
terestingly, a small band is observed running slightly higher 
than the monomer protein (Fig. 1, lane 2) which disappears 
under reducing conditions (Fig. 1, lane 3) which would be 
consistent with the presence of an ITF-glutathione complex. 
As ITF is found within the gastrointestinal tract, the effect 
of pH on the stability of the recombinant ITF homodimer was 
therefore investigated. Purified rITF protein samples were in- 
cubated overnight in phosphate buffer of varying pH (pH 4-7) 
and subsequently analysed by non-reducing SDS-PAGE (Fig. 
1, lanes (~9) and size exclusion chromatography. This treat- 
ment had little effect on the concentration a d/or atio of ITF 
homodimers. 
3.3. Characterisation of the 5ZCys mutant of recomb&ant rlTF 
In order to determine whether the free cysteine residue at the 
C-terminus i involved in the dimerisation ofrITF, site-directed 
mutagenesis was carried out changing Cys s7 to Lys. As shown 
in Fig. 1 (lane 4), the loss of the Cys s7 prevents the interaction 
of recombinant rITF to form homodimers. Interestingly, 
the inability to form dimeric forms of rITF inhibits changes in 
ion transport across confluent cultured epithelial layers, using 
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Fig. 2. Identification of pS2 and ITF in human tissue by Western blot 
analysis. Human intestinal tissue was boiled in Laemmli loading buffer 
with (lanes 1,2 in duplicate) or without (lane 3,4 in duplicate) the 
presence of 2-mercaptoethanol andproteins resolved under non-reduc- 
ing conditions (see section 2). (a) Autograph derived from the above 
gel showing the presence of monomeric and dimeric forms of pS2, the 
positions of which coincide precisely with that of aprotinin (6.5 kDa) 
and lysozyme (14.3 kDa), respectively. (b) Autograph showing asimilar 
arrangement for human ITF. Molecular mass markers are indicated at 
the left hand side (kDa) as in Fig. la. 
voltage-clamp techniques, which have been previously de- 
scribed for the wild-type peptide [21]. 
3.4. Potential dimerisation of human ITF and pS2 in vivo 
The observation that purified recombinant rITF can exist as 
a homodimer suggests that either itself, or other single trefoil- 
containing proteins, may be associated in a similar way in vivo. 
To try and test this hypothesis, homogenised samples of human 
small intestinal tissue obtained from a patient with Crohn's 
disease (a chronic inflammatory bowel disorder associated with 
the over-expression f pS2, SP, and ITF) were analysed by 
Western blotting using a monoclonal antibody to pS2 or the 
polyclonal antisera raised against recombinant rITF (Fig. 2). 
Under non-reducing conditions, two proteins of approximately 
7 and 14 kDa could be observed following pS2 (Fig. 2a: lanes 
1,2) and ITF (Fig. 2b: lanes 1,2) immunostaining. When the 
same sample was electrophoresed under reducing conditions, 
the larger immunoreactive band disappeared (lanes 3,4), sug- 
gesting that both human pS2 and ITF exist as disulphide-linked 
complexes in vivo. The presence of the monomeric form of 
human ITF and pS2 under non-reducing conditions may be due 
in some way to the extraction and/or storage procedures of the 
tissue samples after biopsy, which resulted in an unknown mod- 
ification of the free sulfhydryl. A similar esult was seen for the 
purified recombinant rITF (see above). Due to the similar sizes 
of pS2 and ITF, it is possible that the 14 kDa immunoreactive 
covalent complexes observed in Fig. 2 are pS2/ITF hetero- 
dimers. Although, neither antibody demonstrated cross-reac- 
tivity with the opposing peptide, it is not possible at this stage 
to discriminate between pS2/ITF homo- or heterodimers as 
both peptides are present in the same tissue sample. It is also 
possible that the 14 kDa immunoreactive covalent complexes 
of human pS2 and ITF are disulphide-linked complexes of pS2 
or ITF with unknown proteins of similar sizes to pS2 and ITF. 
However, the molecular modelling studies of the pS2 and ITF 
homodimers ( ee below) combined with the in vitro analysis of 
recombinant rITF support he conclusion that pS2 and ITF can 
exist as covalent dimers in vivo. 
3.5. The pS2 and ITF homodimer models 
The crystal structure of PSP consists of two covalently linked 
trefoil domains (Fig. 3) [(~8]. Inspection of the structure sug- 
gests that single copy members of the trefoil family, such as ITF 
and pS2, could pack together in a similar orientation to the two 
trefoils in PSP, thus forming homodimers. A sequence align- 
ment of the trefoil family shows that human, rITF and pS2 do 
not have the first cysteine of the analogous N-terminal trefoil 
of PSP but an extra cysteine at the C-terminus (Fig. 3a). As all 
other cysteines are conserved it is these terminal cysteines that 
are predicted to link two molecules of either ITF or pS2 to- 
gether. The N and C-terminal trefoil domains of PSP have high 
sequence similarity to ITF and pS2 (Fig. 3a). However, the 
C-terminal PSP trefoil domain (PSPB in Fig. 3a) was thought 
to be the best template for modelling as no insertions or dele- 
tions were necessary within the core of the motif. We modelled 
the hITF homodimer rather than the rITF homodimer, as pS2 
is a human sequences and there is high sequence identity (76%) 
between the mature human and rat ITF proteins, including all 
of the important hydrophobic ore residues and disulphide 
bridges (Fig. 3a). 
Inspection of the sequences and PSP structure indicated that 
the last conserved residue before the C-termini s a proline, six 
residues back from the free cysteine of human ITF (Fig. 3a). 
The remaining residues between this proline and the C-termini 
do not contribute to the structure of the PSP trefoils but some 
do contribute to the interface between trefoils both in the crys- 
tal structure and predicted homodimer interfaces. Other inter- 
face residues common to both the PSP X-ray crystal structure 
and predicted homodimer interfaces are on the whole con- 
served but there are some differences between the crystal struc- 
ture and potential homodimers (Fig. 3a). The most notable is 
the disulphide link at the interface of the homodimers and this 
alone suggests that small adjustments are needed between the 
relative orientations of the trefoil domains. 
Twelve backbone phi/psi angles, six from each domain of 
human ITF starting from the conserved proline and ending 
with the terminal cysteine, were adjusted manually to form the 
inter-trefoil disulphide link. Equal adjustments were made to 
equivalent angles in each trefoil and only allowed regions of the 
Ramachandran phi~psi map [22] were sampled with the best 
packing of residues into the core and between each trefoil 
maintained. Under these constraints a disulphide link could be 
formed. For pS2, there is a five residue insertion in the pS2 
sequence (see Fig. 3a), thus a fragment database search [17] was 
carried out to model this insertion with the endpoints of the 
search fixed. The best fitting fragment chosen was for that of 
a random coil as might be expected ue to the occurrence of 
two consecutive prolines within the insert region (see Fig. 3b). 
The final energy refined ITF and pS2 homodimer models were 
assessed for correct geometry, with both models passing all 
protein health checks set by the program QUANTA [20]. 
The possibility that ITF and pS2 homodimers link via a 
disulphide but with no stabilising homodimer interface, cannot 
be discounted. Indeed, even free rotation of both domains 
around the disulphide bond is possible. However, there is 
enough conservation i both sequence and secondary structure 
at the trefoil interfaces, relative to the known crystal structure 
of PSP, to suggest that the homodimers are stable as modelled. 
Moreover, the modelled intermolecular disulphide link is of 
good geometry and is energetically stable. 
3.5. Functional implications of pS2 and ITF dimerisation 
Does the formation of homo- or heterodimers by ITF and 
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Fig. 3. Amino acid sequence alignments of the trefoil family and three-dimensional models for the pS2 and human ITF homodimers. (a) Multiple 
sequence alignments oftrefoil domains (reviewed in [1]). The top sequence ofeach sequence block PSPA and PSPB are from the X-ray crystal structure 
of PSP. The bottom two sequences of the lower block are the trefoils modelled, human ITF [4], and human breast cancer associated peptide pS2. 
Residues that are 100% conserved in all trefoils are boxed. Disulphide links within and between trefoils are indicated by arrows. The homodimer 
disulphide is indicated by a circular arrow. The symbol ~, indicates the peptide break made between the two trefoil units of PSP. The row labelled 
SS, indicate the position of secondary structure lements as determined from the crystal structure of PSE The row labelled INTERFACE indicate 
those residues that are part of the interface between trefoils both in the crystal structure and predicted homodimers. (b) Model for the homodimers 
of hlTF and pS2 and how they were modelled from PSP. The protein chain of each structure is illustrated as a coloured cylinder. Each trefoil domain 
for the homodimers is in a different colour, green and light blue. Disulphide bonds are indicated by yellow bars. The cysteine that has been lost by 
the homodimers elative to the PSP structure is labelled, C-->NIE, as N is the mutation for hITF and E for pS2 at this position. The cysteine gained 
by the homodimers is labelled by, S---> C. The position of the five residue insert ofpS2 relative to hITF is also labelled. Figure produced with PREPI 
(S. Islam and M. Sternberg, ICRF). 
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pS2 in vivo indicate a functional mechanism? It has been sug- 
gested that trefoil peptides in general, including ITF and pS2, 
may act to stabilise the mucous gel layer since they are co- 
expressed with mucin-type glycoproteins in the human gastro- 
intestinal tract [23]. These mucins are covered by O-linked 
carbohydrates and preliminary modelling studies by us as well 
as by others [6] indicate that some of the surface pockets on 
each trefoil may bind carbohydrate units. Hence, trefoil do- 
mains may bind carbohydrate chains attached to mucins which 
under the right conditions, such as mucosal damage (ulcera- 
tion, injury), the trefoils could form disulphide-linked dimers. 
The cross-linking of mucin chains could effect the viscosity of 
the mucous layer possibly facilitating cellular estitution across 
the damaged area. Interestingly, for secreted mucins, free cys- 
teines on separate mucin molecules cross-link the cores of the 
mucin chains through intermolecular disulphide bonds forming 
the mucous layer [24]. Trefoil peptides could bind to the poly- 
saccharide part of the mucin molecules and provide further 
cross-linking by forming covalent homo- or heterodimers. 
Alternatively, the existence of homo- or heterodimeric forms 
of pS2 and ITF could enable these single trefoil proteins to 
compete with double trefoil-containing proteins for receptor 
sites. High affinity binding sites for PSP have already been 
demonstrated in the rat small intestine [25], and putative bind- 
ing sites for rITF were demonstrated histochemically in the rat 
stomach, kidney, and colon [26], regions of the gut rich in both 
single (pS2, ITF) and double (SP) trefoil-containing proteins. 
It has been suggested previously that the growth stimulatory 
effects of PSP on a human breast carcinoma cell line may be 
mediated by its cross-recognition f a pS2-binding site [27], 
reflecting the related tertiary structures of these trefoil proteins. 
The functional implications of either homo- or heterodimeric 
pS2 and ITF, both physiological nd pathological, will have to 
await further in vitro and in vivo studies. 
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